Trials / Completed
CompletedNCT01225315
Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma
A Multi-center, Double-blind, Placebo-controlled, Parallel-group Study to Establish Proof-of-concept and Explore the Efficacy of Different Doses of ACT-129968 in Adult Patients With Partly Controlled Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 438 (actual)
- Sponsor
- Idorsia Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Matching placebo administered orally twice daily |
| DRUG | Setipiprant | ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2012-01-01
- Completion
- 2012-02-01
- First posted
- 2010-10-21
- Last updated
- 2018-07-09
Locations
97 sites across 13 countries: United States, Australia, Bulgaria, Germany, Hungary, Israel, Poland, Russia, Serbia, Singapore, South Africa, Sweden, Ukraine
Source: ClinicalTrials.gov record NCT01225315. Inclusion in this directory is not an endorsement.